$CLRB
Cellectar Biosciences, Inc.

2018 Q4 Form 10-Q Financial Statement

#000114420418059004 Filed on November 13, 2018

View on sec.gov

Income Statement

Concept 2018 Q4 2018 Q3 2018 Q2
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.170M $1.090M $1.180M
YoY Change 18.18% -5.22% 13.46%
% of Gross Profit
Research & Development $1.040M $1.996M $1.723M
YoY Change -66.45% -14.47% -20.81%
% of Gross Profit
Depreciation & Amortization $30.00K $20.00K $10.00K
YoY Change -97.62% -80.0% -90.0%
% of Gross Profit
Operating Expenses $2.200M $1.996M $1.723M
YoY Change -46.21% -14.47% -20.81%
Operating Profit -$3.087M -$2.905M
YoY Change -11.37% -9.69%
Interest Expense $60.00K $6.558K $4.228K
YoY Change 500.0% 65.23% -14.43%
% of Operating Profit
Other Income/Expense, Net $72.56K -$15.77K
YoY Change 455.19% -116.61%
Pretax Income -$3.830M -$3.010M -$2.920M
YoY Change -6.13% -13.26% -6.41%
Income Tax
% Of Pretax Income
Net Earnings -$3.830M -$3.015M -$2.921M
YoY Change -6.13% -13.13% -6.43%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$732.3K -$946.5K -$1.688M
COMMON SHARES
Basic Shares Outstanding 4.758M shares 3.595M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2018 Q4 2018 Q3 2018 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $13.26M $16.37M $4.180M
YoY Change 32.47% 189.22% -49.7%
Cash & Equivalents $13.26M $16.37M $4.181M
Short-Term Investments
Other Short-Term Assets $700.0K $750.0K $840.0K
YoY Change 48.94% -27.18% -18.45%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $13.95M $17.11M $5.016M
YoY Change 33.21% 155.82% -46.29%
LONG-TERM ASSETS
Property, Plant & Equipment $543.3K $192.0K $212.0K
YoY Change 122.03% -87.2% -86.58%
Goodwill $0.00 $1.675M $1.675M
YoY Change -100.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $18.09K $18.09K $93.09K
YoY Change 52.34% 80.86% 830.86%
Total Long-Term Assets $1.102M $2.426M $1.981M
YoY Change -54.03% -23.7% -39.25%
TOTAL ASSETS
Total Short-Term Assets $13.95M $17.11M $5.016M
Total Long-Term Assets $1.102M $2.426M $1.981M
Total Assets $15.05M $19.54M $6.997M
YoY Change 16.96% 97.98% -44.47%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $612.0K $2.570M $2.090M
YoY Change -34.41% 27.23% 42.18%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00 $0.00 $0.00
YoY Change
Total Short-Term Liabilities $1.622M $2.661M $2.289M
YoY Change -23.3% 24.91% 43.98%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $170.0K
YoY Change
Total Long-Term Liabilities $171.0K $0.00 $568.00
YoY Change 7627.02% -100.0% -99.59%
TOTAL LIABILITIES
Total Short-Term Liabilities $1.622M $2.661M $2.289M
Total Long-Term Liabilities $171.0K $0.00 $568.00
Total Liabilities $1.793M $2.661M $2.290M
YoY Change -15.3% 16.69% 31.6%
SHAREHOLDERS EQUITY
Retained Earnings -$97.59M -$93.76M -$90.75M
YoY Change 15.7% 16.81%
Common Stock $47.00 $43.00 $17.00
YoY Change 193.75% -68.15%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $13.26M $16.88M $4.707M
YoY Change
Total Liabilities & Shareholders Equity $15.05M $19.54M $6.997M
YoY Change 16.96% 97.95% -44.47%

Cashflow Statement

Concept 2018 Q4 2018 Q3 2018 Q2
OPERATING ACTIVITIES
Net Income -$3.830M -$3.015M -$2.921M
YoY Change -6.13% -13.13% -6.43%
Depreciation, Depletion And Amortization $30.00K $20.00K $10.00K
YoY Change -97.62% -80.0% -90.0%
Cash From Operating Activities -$2.740M -$2.970M -$2.550M
YoY Change -3.18% 16.93% -4.14%
INVESTING ACTIVITIES
Capital Expenditures -$380.0K $0.00 $0.00
YoY Change -100.0% -100.0%
Acquisitions
YoY Change
Other Investing Activities $10.00K $50.00K
YoY Change
Cash From Investing Activities -$370.0K $40.00K $0.00
YoY Change -233.33% -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 15.11M -90.00K
YoY Change -100.0% -18987.5% 800.0%
NET CHANGE
Cash From Operating Activities -2.740M -2.970M -2.550M
Cash From Investing Activities -370.0K 40.00K 0.000
Cash From Financing Activities 0.000 15.11M -90.00K
Net Change In Cash -3.110M 12.18M -2.640M
YoY Change -171.66% -559.62% -9.59%
FREE CASH FLOW
Cash From Operating Activities -$2.740M -$2.970M -$2.550M
Capital Expenditures -$380.0K $0.00 $0.00
Free Cash Flow -$2.360M -$2.970M -$2.550M
YoY Change -16.61% 18.33% 5.81%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2018Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
16373474 USD
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
10006421 USD
CY2018Q3 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
55000 USD
CY2017Q4 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
55000 USD
CY2018Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
685967 USD
CY2017Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
412173 USD
CY2018Q3 us-gaap Assets Current
AssetsCurrent
17114441 USD
CY2017Q4 us-gaap Assets Current
AssetsCurrent
10473594 USD
CY2018Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
191984 USD
CY2017Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
244713 USD
CY2018Q3 us-gaap Goodwill
Goodwill
1675462 USD
CY2017Q4 us-gaap Goodwill
Goodwill
1675462 USD
CY2018Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
18086 USD
CY2017Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
11872 USD
CY2018Q3 us-gaap Assets
Assets
19540796 USD
CY2017Q4 us-gaap Assets
Assets
12871464 USD
CY2018Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
2571550 USD
CY2017Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
1867758 USD
CY2018Q3 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
0 USD
CY2017Q4 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
138944 USD
CY2018Q3 us-gaap Capital Lease Obligations Current
CapitalLeaseObligationsCurrent
3003 USD
CY2017Q4 us-gaap Capital Lease Obligations Current
CapitalLeaseObligationsCurrent
3036 USD
CY2018Q3 us-gaap Liabilities Current
LiabilitiesCurrent
2660553 USD
CY2017Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2114788 USD
CY2018Q3 us-gaap Capital Lease Obligations Noncurrent
CapitalLeaseObligationsNoncurrent
0 USD
CY2017Q4 us-gaap Capital Lease Obligations Noncurrent
CapitalLeaseObligationsNoncurrent
2213 USD
CY2018Q3 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
0 USD
CY2017Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
2213 USD
CY2018Q3 us-gaap Liabilities
Liabilities
2660553 USD
CY2017Q4 us-gaap Liabilities
Liabilities
2117001 USD
CY2018Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2017Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
43575 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-346703 USD
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
0 USD
CY2018Q3 us-gaap Common Stock Value
CommonStockValue
43 USD
CY2017Q4 us-gaap Common Stock Value
CommonStockValue
16 USD
CY2018Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
107126925 USD
CY2017Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
94107981 USD
CY2018Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-93760764 USD
CY2017Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-84349316 USD
us-gaap Share Based Compensation
ShareBasedCompensation
512913 USD
us-gaap Share Based Compensation
ShareBasedCompensation
573084 USD
us-gaap Derivative Instruments Not Designated As Hedging Instruments Gain Loss Net
DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
19050 USD
us-gaap Derivative Instruments Not Designated As Hedging Instruments Gain Loss Net
DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
16625 USD
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
703792 USD
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
602798 USD
CY2018Q3 us-gaap Stockholders Equity
StockholdersEquity
16880243 USD
CY2018Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
72558 USD
CY2017Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
13069 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
34490 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
28922 USD
CY2018Q3 us-gaap Net Income Loss
NetIncomeLoss
-3014934 USD
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
10754463 USD
CY2018Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
19540796 USD
CY2017Q3 us-gaap Net Income Loss
NetIncomeLoss
-3470699 USD
CY2018Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.65
CY2017Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.58
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-5.29
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-7.30
CY2018Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
3184856 shares
CY2017Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
1347097 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
2204554 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
1298643 shares
CY2017Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
105050 USD
us-gaap Net Income Loss
NetIncomeLoss
-9411448 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
50051 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
294195 USD
CY2017Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
12871464 USD
CY2018Q3 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
49425 shares
CY2017Q4 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
53306 shares
CY2018Q3 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
86000 USD
CY2018Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1995571 USD
CY2017Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2333058 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5798526 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6365868 USD
CY2018Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1091921 USD
CY2017Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1150710 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3647412 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3146605 USD
CY2018Q3 us-gaap Costs And Expenses
CostsAndExpenses
3087492 USD
CY2017Q3 us-gaap Costs And Expenses
CostsAndExpenses
3483768 USD
us-gaap Costs And Expenses
CostsAndExpenses
9445938 USD
us-gaap Costs And Expenses
CostsAndExpenses
9512473 USD
CY2018Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-3087492 USD
CY2017Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-3483768 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-9445938 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-9512473 USD
CY2018Q3 us-gaap Derivative Instruments Not Designated As Hedging Instruments Gain Loss Net
DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
66000 USD
CY2017Q3 us-gaap Derivative Instruments Not Designated As Hedging Instruments Gain Loss Net
DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
9100 USD
us-gaap Derivative Instruments Not Designated As Hedging Instruments Gain Loss Net
DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
19050 USD
us-gaap Derivative Instruments Not Designated As Hedging Instruments Gain Loss Net
DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
16625 USD
CY2018Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
6558 USD
CY2017Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
3969 USD
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
15440 USD
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
12297 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
273794 USD
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
2963259 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
160334 USD
us-gaap Increase Decrease In Other Operating Capital Net
IncreaseDecreaseInOtherOperatingCapitalNet
220158 USD
us-gaap Increase Decrease In Other Operating Capital Net
IncreaseDecreaseInOtherOperatingCapitalNet
3801 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-8698592 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-8194234 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1425 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
346703 USD
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
0 USD
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
86591 USD
us-gaap Repayments Of Long Term Capital Lease Obligations
RepaymentsOfLongTermCapitalLeaseObligations
2246 USD
us-gaap Repayments Of Long Term Capital Lease Obligations
RepaymentsOfLongTermCapitalLeaseObligations
1786 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
15022070 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2758545 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
6367053 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-5782392 USD
CY2017Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
10061421 USD
CY2016Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
11499619 USD
CY2018Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
16428474 USD
CY2017Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
5717227 USD
us-gaap Interest Paid Net
InterestPaidNet
0 USD
us-gaap Interest Paid Net
InterestPaidNet
364 USD
CY2018Q3 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
5318747 shares
CY2018Q3 us-gaap Share Based Compensation
ShareBasedCompensation
163896 USD
CY2017Q3 us-gaap Share Based Compensation
ShareBasedCompensation
176324 USD
clrb Employee Service Share Based Compensation Nonvested Total Compensation In Current Year
EmployeeServiceShareBasedCompensationNonvestedTotalCompensationInCurrentYear
170000 USD
clrb Employee Service Share Based Compensation Nonvested Total Compensation In Year Two
EmployeeServiceShareBasedCompensationNonvestedTotalCompensationInYearTwo
480000 USD
clrb Employee Service Share Based Compensation Nonvested Total Compensation In Year Three
EmployeeServiceShareBasedCompensationNonvestedTotalCompensationInYearThree
96000 USD
CY2018Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
753000 USD
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
45.67
CY2018Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
21.34 shares
clrb Proceeds From Deferred Issuance Costs
ProceedsFromDeferredIssuanceCosts
0 USD
clrb Proceeds From Deferred Issuance Costs
ProceedsFromDeferredIssuanceCosts
-116337 USD
clrb Employee Service Share Based Compensation Nonvested Total Compensation In Year Four
EmployeeServiceShareBasedCompensationNonvestedTotalCompensationInYearFour
7000 USD
CY2018Q2 us-gaap Area Of Land
AreaOfLand
3983 sqft
CY2018Q2 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P64M
CY2018Q2 clrb Proceeds To Be Received For Tenant Improvements
ProceedsToBeReceivedForTenantImprovements
179235 USD
CY2018Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
828000 USD
CY2018Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
783000 USD
CY2018Q3 us-gaap Finance Lease Liability
FinanceLeaseLiability
267000 USD
CY2018Q2 us-gaap Lessee Operating Lease Option To Extend
LesseeOperatingLeaseOptionToExtend
The Company also has an option to extend the term of the lease for one additional 60-month period
clrb Payments For Leases Security Deposits
PaymentsForLeasesSecurityDeposits
75000 USD
CY2018Q3 us-gaap Long Term Investments
LongTermInvestments
540823 USD
CY2017Q4 us-gaap Long Term Investments
LongTermInvestments
465823 USD
CY2018Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2018Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
80000000 shares
CY2017Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2017Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
80000000 shares
CY2018Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
4269989 shares
CY2017Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1666144 shares
CY2018Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
4269989 shares
CY2017Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1666144 shares
CY2017Q3 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
1355000 shares
CY2017Q3 us-gaap Convertible Preferred Stock Shares Issued Upon Conversion
ConvertiblePreferredStockSharesIssuedUponConversion
2785000 shares
CY2017Q3 us-gaap Share Price
SharePrice
4.00
CY2017Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
4.00
CY2017Q3 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
16560000 USD
CY2017Q3 us-gaap Class Of Warrant Or Righst Date From Which Warrants Or Rights Exercisable
ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable
2023-07-31
CY2017Q3 clrb Net Proceeds From Issuance Or Sale Of Equity After Deducting Underwriting Discounts And Commissions And Related Offering Expenses
NetProceedsFromIssuanceOrSaleOfEquityAfterDeductingUnderwritingDiscountsAndCommissionsAndRelatedOfferingExpenses
15030000 USD
CY2018Q3 us-gaap Preferred Stock Dividends And Other Adjustments
PreferredStockDividendsAndOtherAdjustments
2241795 USD
CY2017Q3 us-gaap Preferred Stock Dividends And Other Adjustments
PreferredStockDividendsAndOtherAdjustments
0 USD
us-gaap Preferred Stock Dividends And Other Adjustments
PreferredStockDividendsAndOtherAdjustments
2241795 USD
us-gaap Preferred Stock Dividends And Other Adjustments
PreferredStockDividendsAndOtherAdjustments
0 USD
CY2018Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-5256729 USD
CY2017Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-3470699 USD
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-11653243 USD
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-9483551 USD
us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;">Reclassifications</div></div></div><div style="font-family: &quot;times new roman&quot;, times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> &#8212; Certain amounts in prior periods have been reclassified to conform to the current year presentation. Such classifications did not have a material effect on the Company&#8217;s financial condition or results of operations as previously reported.</div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
40898 USD
us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
0 USD
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
45000 USD
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
0 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
9075777 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0 USD
us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
5949301 USD
us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
0 USD
clrb Reverse Stock Split Fractional Shares
ReverseStockSplitFractionalShares
762 USD
clrb Reverse Stock Split Fractional Shares
ReverseStockSplitFractionalShares
0 USD
CY2018Q3 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
At a special meeting held on July 12, 2018, our stockholders approved an amendment to our certificate of incorporation to affect a reverse split of our common stock at a ratio between 1:5 to 1:10 and authorized the Board to determine the ratio at which the reverse split would be. The Board authorized the ratio of the reverse split, and effective at the close of business on July 16, 2018, the Company implemented a 1-for-10 reverse stock split of its outstanding common stock. The accompanying condensed consolidated financial statements and accompanying notes to the condensed consolidated financial statements give retroactive effect to the reverse stock split for all periods presented. The shares of common stock that the Company is authorized to issue remains unchanged at 80,000,000 and the par value remains at $0.00001 per share. Accordingly, stockholders' equity reflects the reverse stock split by reclassifying from common stock to additional paid-in capital an amount equal to the par value of the decreased shares resulting from the reverse stock split.
CY2016Q4 us-gaap Stockholders Equity
StockholdersEquity
13539872 USD
CY2017Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
0 USD
CY2017Q1 clrb Stock Issued During Period On Exercise Of Warrants Value
StockIssuedDuringPeriodOnExerciseOfWarrantsValue
2934759 USD
CY2017Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
165674 USD
CY2017Q1 us-gaap Net Income Loss
NetIncomeLoss
-2891324 USD
CY2017Q1 us-gaap Stockholders Equity
StockholdersEquity
13748981 USD
CY2017Q2 clrb Stock Issued During Period On Exercise Of Warrants Value
StockIssuedDuringPeriodOnExerciseOfWarrantsValue
6000 USD
CY2017Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
231086 USD
CY2017Q2 us-gaap Net Income Loss
NetIncomeLoss
-3121528 USD
CY2017Q2 us-gaap Stockholders Equity
StockholdersEquity
10864539 USD
CY2017Q3 clrb Stock Issued During Period On Exercise Of Warrants Value
StockIssuedDuringPeriodOnExerciseOfWarrantsValue
22500 USD
CY2017Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
176324 USD
CY2017Q3 us-gaap Stockholders Equity
StockholdersEquity
7592664 USD
CY2018Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
0 USD
CY2018Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
173438 USD
CY2018Q1 us-gaap Net Income Loss
NetIncomeLoss
-3475823 USD
CY2018Q1 us-gaap Stockholders Equity
StockholdersEquity
7452078 USD
CY2018Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
0 USD
CY2018Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
175579 USD
CY2018Q2 us-gaap Net Income Loss
NetIncomeLoss
-2920691 USD
CY2018Q2 us-gaap Stockholders Equity
StockholdersEquity
4706966 USD
CY2018Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
15025077 USD
CY2018Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
0 USD
CY2018Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
163896 USD
CY2018Q3 us-gaap Adjustments To Additional Paid In Capital Stock Split
AdjustmentsToAdditionalPaidInCapitalStockSplit
-762 USD
us-gaap Net Income Loss
NetIncomeLoss
-9483551 USD
CY2018Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
0 USD
CY2018Q2 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
0 USD
CY2018Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.00001
CY2017Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.00001
CY2018Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
7000 shares
CY2017Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
7000 shares
dei Document Type
DocumentType
10-Q
dei Amendment Flag
AmendmentFlag
false
dei Document Period End Date
DocumentPeriodEndDate
2018-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2018
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Registrant Name
EntityRegistrantName
Cellectar Biosciences, Inc.
dei Entity Central Index Key
EntityCentralIndexKey
0001279704
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Trading Symbol
TradingSymbol
CLRB
CY2018Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
4757786 shares
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Small Business
EntitySmallBusiness
true

Files In Submission

Name View Source Status
0001144204-18-059004-index-headers.html Edgar Link pending
0001144204-18-059004-index.html Edgar Link pending
0001144204-18-059004.txt Edgar Link pending
0001144204-18-059004-xbrl.zip Edgar Link pending
clrb-20180930.xml Edgar Link completed
clrb-20180930.xsd Edgar Link pending
clrb-20180930_cal.xml Edgar Link unprocessable
clrb-20180930_def.xml Edgar Link unprocessable
clrb-20180930_lab.xml Edgar Link unprocessable
clrb-20180930_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tv505892_10q.htm Edgar Link pending
tv505892_ex10-3.htm Edgar Link pending
tv505892_ex10-4.htm Edgar Link pending
tv505892_ex10-5.htm Edgar Link pending
tv505892_ex31-1.htm Edgar Link pending
tv505892_ex31-2.htm Edgar Link pending
tv505892_ex32-1.htm Edgar Link pending